Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP547703.RAc04-rnnEUulQoEe3UWBmfPIaEcd9_R3MAKSxKV0_A-4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP547703.RAc04-rnnEUulQoEe3UWBmfPIaEcd9_R3MAKSxKV0_A-4130_assertion type Assertion NP547703.RAc04-rnnEUulQoEe3UWBmfPIaEcd9_R3MAKSxKV0_A-4130_head.
- NP547703.RAc04-rnnEUulQoEe3UWBmfPIaEcd9_R3MAKSxKV0_A-4130_assertion description "[epidermal growth factor receptor), along with the introduction of FDA approved pharmacogenetic tests (UGT1A1*28) and the initiation of a genotype-guided clinical trial for cancer therapy (TYMS TSER in rectal cancer) have provided the first steps towards the integration of pharmacogenomics into clinical practice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP547703.RAc04-rnnEUulQoEe3UWBmfPIaEcd9_R3MAKSxKV0_A-4130_provenance.
- NP547703.RAc04-rnnEUulQoEe3UWBmfPIaEcd9_R3MAKSxKV0_A-4130_assertion evidence source_evidence_literature NP547703.RAc04-rnnEUulQoEe3UWBmfPIaEcd9_R3MAKSxKV0_A-4130_provenance.
- NP547703.RAc04-rnnEUulQoEe3UWBmfPIaEcd9_R3MAKSxKV0_A-4130_assertion SIO_000772 16651374 NP547703.RAc04-rnnEUulQoEe3UWBmfPIaEcd9_R3MAKSxKV0_A-4130_provenance.
- NP547703.RAc04-rnnEUulQoEe3UWBmfPIaEcd9_R3MAKSxKV0_A-4130_assertion wasDerivedFrom befree-2016 NP547703.RAc04-rnnEUulQoEe3UWBmfPIaEcd9_R3MAKSxKV0_A-4130_provenance.
- NP547703.RAc04-rnnEUulQoEe3UWBmfPIaEcd9_R3MAKSxKV0_A-4130_assertion wasGeneratedBy ECO_0000203 NP547703.RAc04-rnnEUulQoEe3UWBmfPIaEcd9_R3MAKSxKV0_A-4130_provenance.